

The autonomic innervation of the uterus

A short review on pharmacological aspects

Andrei Adrian Tica¹,
Erika Dun²,
Vlad Tica³,
Victor Cojocaru⁴, Oana Sorina Tica¹,
Sabina Berceanu⁵

1. Department of Pharmacology, University of Medicine and Pharmacy Craiova, Romania,

2. Department of Pharmacology, School of Medicine, Temple University of Philadelphia, USA

3. Department of Obstetrics and Gynecology, Faculty of Medicine, University of Constanta, Romania

4. Department of Anesthesiology, University of Medicine and Pharmacy Kishinev, Moldova

5. Department of Obstetrics and Gynecology, University Hospital Craiova, Romania

Correspondence: Andrei Adrian Tica, e-mail: ticaandrei2002@yahoo.com
Oana-Sorina Tica, e-mail: oanabanica25@yahoo.com

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. The article has not been presented in public or considered for publication elsewhere.

Abstract

Despite the important volume of data regarding the physiology and pharmacology of uterine smooth muscle innervation, it is unclear the precise role of the nervous supply on myometrial activity. Moreover, although all uterine myocytes possess specific adrenergic and cholinergic receptors, the autonomic fibers are almost exclusively distributed to cervix (eventually to isthmus, which becomes the lower uterine segment in the last part of the pregnancy), where is located less than 10% of the whole myometrium. It seems that neuronal modulation is implicated more on cervical dynamics and poorly on "effective" uterine contractility. It is important to note that constantly there is a neuronal co-transmission, either sympathetic or parasympathetic, or even non-adrenergic/non-cholinergic mediation, the number of discovered compounds, able to modulate the uterine activity, increasing permanently. Must be mentioned, also, the variability of receptors either as density, sensitivity or intracellular pathways, depending of hormonal impregnation, especially on gestation. Furthermore, during pregnancy, placenta and amniotic membranes possess a strong impact on myometrium, connective tissue, but also on neuronal ending characteristics.

Keywords: sympathetic, parasympathetic, co-transmission, non-adrenergic non-cholinergic

Introduction

Although there is enough information about both morphological and pharmacological characteristics of uterine autonomic nervous supply, the precise importance of the neurological component on uterine modulation, remains to be determined.

The autonomic nervous fibers, distributed to the uterus, release noradrenaline (from sympathetic endings), acetylcholine (from parasympathetic fibers), but also a great number of other compounds, which, beside the two main neurotransmitters, can modulate myometrial activity.

It must be mentioned the strong hormonal dependence of the local specific receptors for almost all neuromediators, either as type (or subtype), density, sensitivity or intracellular signalling pathways.

Furthermore, the association of placenta and amniotic membranes during pregnancy, modify, supplementary, not only the myometrial sensitivity to local neurotransmitters, but also the regional nervous fibers either as density or mediators release.

The labor progression and the autonomic nervous supply. A continuous positive cycle

The progression of the fetus through the genital channel causes distension of the lower segment and, especially, of the cervix. Excitation of the local nerve endings induces (at least theoretically) hypothalamic oxytocin release, with increased uterine activity (Fergusson reflex).

Moreover, also through a cervical reflex mechanism, it is stimulated the release of neuromediators from periuterine nerve endings, with contractile effects. In the same time, the exocytosis of secretoneurin from

the same nerve endings (also induced by local tissue distention), leads to local increased density of leukocytes, particularly macrophages, cells with important roles on cervical dynamics⁽¹⁾.

As labor progresses, the distension of the vagina, uterine ligaments and surrounding organs, also by reflex mechanism, accelerates myometrial contractility.

A fundamental role also plays the rectal distension, which, in addition to inducing ejection reflex (abdominal press is especially important for fetal expulsion), stimulates uterine contractility and, especially, accelerates cervix effacement and dilation. The histochemical identification could support this clinical observation of particular autonomic nerves, which make a direct reflex arc rectum-marrow-cervix⁽²⁾.

Even distension or dissociation of the perineal various somatic components, either directly⁽³⁾ or indirectly, through intense pain sensation, accelerate the uterine contractility⁽⁴⁾.

In the same time, all these phenomenons, occurring in response to the involvement of various structures during fetal progression, are accompanied by local hemodynamic changes, appropriates for the purposes of enhancing irrigation in the utero-vaginal area⁽³⁾.

General pharmacological aspects on uterine autonomic innervation

Uterine innervation has two components:

- one afferent, interoceptive type, which is responsible for transmitting information to the central nervous system (this component is not an issue for this paper) and
- efferent, autonomic type.

It is important to note that in myometrium (as in other types of smooth muscle) there is neither direct

contact between axonal endings and myocytes, nor specialized structures, synapses, the neurotransmitter being released (by exocytosis) in the perifascicular space, stimulating different receptors, situated on the muscular cells membrane. It is however, some limitation of the area in which the neural discharge takes place, the so-called „diffuse synapses”⁽⁵⁾.

Knowing that axonal branches finish in the matrix surrounding muscle bundles, it is clear that only smooth fibers located on the outside may be directly stimulated by neurotransmitters. The inside cells (which has no innervation) will be stimulated indirectly by action potentials from outer fibers, especially through “gap” junctions.

Typically, axonal endings in smooth muscle, all unmyelinated, present numerous varicosities, where there are stored the specific neurotransmitters for each type of autonomous innervation⁽⁵⁾ (figure 1). The containing active substances are released, by exocytosis, either following the arrival of an impulse along the axon or spontaneously.

Uterine innervation is strongly dependent, both morphologically and functionally, on the hormonal impregnation. Paradoxically, however, unlike the actions on the myometrium, estrogens inhibit the development of uterine innervation, the sympathetic system being far more affected. This can be demonstrated in experimental conditions, when estrogens are used at high doses during animal growth⁽⁶⁾.

In clinic, during normal pregnancy (in conditions of extremely high estrogen concentrations), there is a gradual decrease in the ratio between the number of nervous fibers and muscle bundles⁽⁶⁾. (Note that, however, the number of both structures significantly increase, in real value, during pregnancy). This phenomenon may contribute to the continuous decrease of the myometrium activity until term, despite the very marked amplification of its contractile capacity, resulting from its strong hypertrophy.

It was also noted that other particular circumstances may influence uterine innervation:

- adenomyosis (the presence of endometrial tissue in uterine muscle) is accompanied by reduction up to disappearance of nerve endings around the lesion⁽⁷⁾;
- inflammatory pelvic diseases, by contrast, increase neural density terminals intra and periuterine⁽⁷⁾, being a cause of the intense pain, which accompany, cvasipermanent, this gynecological pathology.

Classically, there are two types of autonomous innervation:

- adrenergic or sympathetic, which is the most important⁽⁴⁾, and
- cholinergic or parasympathetic.

In reality, however, autonomous innervation is far more complex, involving almost constantly, several types of co-transmission, even non-adrenergic/non-cholinergic fibers (see below).

Regardless of type, the autonomous efferent pathway is consisting from two neurons, the first located in the side horn of the spinal cord, and the second in vegetative ganglia.




Figure 1. The scheme of the innervation of a uterine smooth muscle bundle. (SMC = Smooth muscle cell; Nc = Nucleus; Vv = Varicosities)

Sympathetic or adrenergic innervation

Autonomic uterine innervation is largely of sympathetic type⁽⁴⁾. Sympathetic fibers, represented by the axons of postganglionic neurons, have their origins in paraspinal ganglia tail-10-lumbar 1. Axonal endings, that reach the uterus, are distributed throughout the musculature, especially the cervical area.

Terminal knobs, belonging to final sympathetic ramifications, contain vesicles with: noradrenaline (responsible for the adrenergic effects), dopamine β -hydroxylase (the enzyme that converts dopamine to noradrenaline), adenosine triphosphate (ATP), cromogranin and other proteins.

Noradrenaline intensely stimulates α_1 receptors, more poorly the α_2 and β_1 receptors⁽⁸⁾, β_2 effects being reduced⁽⁹⁾.

Uterine muscle cells, belonging to circular bundles (so in the cervico-isthmic area), possess, especially, type α_1 adrenergic receptors (α_{1A}), with contractil effect, while those from the uterine body, mainly possess β_2 adrenergic receptors, which induce tocolysis (table 1).

Despite the lower number of α_1 receptors face to β_2 in uterine muscle (situated mainly in the uterine body), because the low affinity of noradrenaline for β_2 receptors, this catecholamine induces contraction, both *in vivo* and *in vitro*, regardless of the uterine region. Even during pregnancy when there is a marked increase in the ratio β_2/α_1 receptors (this contributing to the uterine hipoccontractility, absolutely required to maintain pregnancy), noradrenaline maintains ocytotic action.

So, automatically, the sympathetic nervous system stimulation, where nordarenaline is the main mediator, will lead, invariably, to ocytotic effect.

It is important to note that in the last weeks of pregnancy occurs a desensitization of β_2 receptors, being possible that this phenomenon contribute to the initiating of the labor to term⁽¹⁰⁾. In the same direction comes the observation that the number of α_1 receptors increases linearly until term⁽¹¹⁾ (but still well below the β_2), which, associated to β_2 receptor desensitization, could contribute to labor induction.

On the uterine smooth muscle cell membrane there were also identified α_2 receptors, including all their

Table 1

The main neurotransmitters contained in the varicosities of uterine nervous endings, their specific receptors on myometrial smooth muscle cells, intracellular signaling pathways involved and their effects on uterine contraction

Neuromediator		Uterine smooth muscle cells receptors		Intracellular signaling pathways activated	Effects on myometrium
NOR-ADRENALINE	α	α _{1A}		PLC/PIP ₂ /IP ₃ /DAG/Ca ²⁺ (5) PLA ₂ /AHA/PG (leukotrienes) AC (-) → cAMP (-) L-calcium channels (+) → [Ca ²⁺] _i (+)	Contraction Contraction Contraction Contraction
		α _{2A} (α _{2B} , α _{2C})	„Post-synaptic“	PLC/PIP ₂ /IP ₃ /DAG/Ca ²⁺ (26) AC (-) → AMPc (-) ⁽²⁷⁾	Contraction Contraction
			„Pre-synap-tic“ ⁽⁵⁾	AC (-) → cAMP (-) K ⁺ channels (+) L-calcium channels (-) → [Ca ²⁺] _i (-)	All decrease the norepinephrine release from sympathetic endings
	β	β ₂		AC (+) → AMPc (+)	Tocolysis Antimitogen effect ⁽²⁸⁾
		β ₁ , β ₃ ^(9,14)		Ca ²⁺ - sensitive K ⁺ channels (+) ⁽¹²⁾ ATP - sensitive K ⁺ channels (+) ⁽²⁹⁾	Tocolysis Tocolysis
ACETYLCHOLINE	M	M ₃		PLC/PIP ₂ /IP ₃ /DAG/Ca ²⁺ Ca ²⁺ - sensitive K ⁺ channels (+) ⁽¹²⁾ ATP - sensitive K ⁺ channels (+) ⁽³⁰⁾	Contraction Contraction Contraction
		M ₂		AC (-) → cAMP (-) ⁽¹⁶⁾	Contraction
ATP	P1 (A)	A ₁ ⁽¹⁹⁾		Only during pregnancy AC (-) → cAMP (-)	Contraction ⁽³¹⁾
				Only on non-pregnant uterus PLC/PIP ₂ /IP ₃ /DAG/Ca ²⁺	Contraction ⁽³¹⁾
	P2	P _{2y2} ⁽³²⁾		PLC/PIP ₂ /IP ₃ /DAG/ Ca ²⁺ (33) PLA ₂ /AHA/PG (leukotrienes) ⁽³²⁾	Contraction ^(12,32)
P _{2x4} ⁽³⁴⁾ (P _{2x1} *2,3,5,6,7)		[Ca ²⁺] _i (+)	Contraction		
Tachykinins	SP NKA	NK ₂ - NKA > SP ^(21,35,36)		PLC/PIP ₂ /IP ₃ /DAG/Ca ²⁺ (37)	Contraction ⁽²⁵⁾
		NK ₁ - SP > NKA NK ₃ - NKA > SP		PLC/PIP ₂ /IP ₃ /DAG/Ca ²⁺ (21)	?
NPY		Y ₁ ⁽³⁸⁾		AC (-) → AMPc (-) ⁽⁷⁾ PLC/PIP ₂ /IP ₃ /DAG/Ca ²⁺	Contraction ⁽³⁹⁾
Galanin		GAL-R ₁		PLC/PIP ₂ /IP ₃ /DAG/Ca ²⁺	Contraction
Gastric releasing peptide (Bombesin)		GPCR ⁽⁴⁰⁾		PLC/PIP ₂ /IP ₃ /DAG/Ca ²⁺ (40)	Contraction ⁽⁴¹⁾
CCRP		CGRP-B CGRP-A Their density increases during pregnancy and decrease near term ^(42,43,44)		Ca ²⁺ -sensitive K ⁺ channels (+) ⁽⁴⁵⁾ ATP - sensitive K ⁺ channels (+) ⁽⁴⁶⁾	Tocolysis (Possibly it contributes to the specific uterine „hipontractility“ during pregnancy. This action is decreasing to term.)

VIP		VIP-1 VIP-2	GPCR ⁽⁴⁷⁾	AC (+) → cAMP (+) ^(3,47)	Tocolysis ⁽⁴⁷⁾
ANP		ANP-A ANP-B Their density decreases during pregnancy term ⁽⁴⁸⁾		cGMP (+) → PKG (+) ⁽⁴⁹⁾	Tocolysis ⁽⁵⁰⁾
NO		GC ⁽²⁰⁾		GC (+) → cGMP (+)	Tocolysis
		Ca ²⁺ - sensitive K ⁺ channels (+) ^(12,51)			Tocolysis
		ATP - sensitive K ⁺ channels (+) ⁽²²⁾			Tocolysis
		The sensibility increases during the second part of the pregnancy and decreases rapidly near term and especially in labor. (Any contribution to the physiological uterine characteristics during pregnancy?) ⁽⁵²⁾			
Opioids	END	Exist only during pregnancy ⁽⁵³⁾	μ END>ENK	?	No proven effect on myometrial smooth muscle cells. Different effects on local neurons, placenta, amniotic membranes, connective cells etc.
	ENK		k ENK>END		
Dopamine		No receptors ⁽¹²⁾		---	Different effects on local neurons, endometrium, placenta, connective cells etc.
Colecistokinin		?		?	?
Somatostatin		?		?	?

(PLC = Phospholipase C; PIP₂ = Phosphatidylinositol 4,5-bisphosphate^(4,5) IP₃ = Inositol triphosphate^(1,4,5); DAG = diacylglycerol; PLA₂ = phospholipase A₂; AHA = arachidonic acid; cGMP = cyclic guanosine monophosphate; PGs = prostaglandins; AC = adenylyl cyclase; cAMP = cyclic adenosine monophosphate; P₂ = purinergic receptor 2; [Ca²⁺]_i = intracellular calcium; SP = substance P; NKA = Neurokinin A; NK₂ = neurokinin receptor 2; NPY = neuropeptide Y; GPCR = G Protein-coupled Receptor; CGRP = calcitonin gene-related peptide; ANP = atrial natriuretic peptide; VIP = vasoactive intestinal peptide; GC = guanylyl cyclase; PKG = protein kinase G; NO = nitric oxide; END = endorphins; ENK = enkephalins); (The bolded and colored data are considered the most important, ⁽¹⁾ marks the corresponding reference)

subtypes: A, B, C (predominantly α_{2A}; 12), also with contractile effect⁽¹²⁾ (table 1). Unlike α₁ receptors, after a linear increase during pregnancy, there is a marked desensitization of the α₂ receptors within birth⁽¹¹⁾.

α₂ adrenergic receptors can be located on the uterine myocyte membrane ("postsynaptic") but, more importantly, on the sympathetic nerve endings membranes, ("presynaptic"), inhibiting the catecholamines release from the adrenergic fibers⁽¹³⁾.

In the same time, myometrial cells possess β₁⁽¹⁴⁾ and β₃ receptors⁽¹³⁾, both with tocolytic effect (through the same mechanisms as β₂ receptors) (table 1).

But the biological impact of α₂, β₁ and β₃ receptors, on the modulation of uterine contractility, remains to be decided.

There have been identified, in the periuterine area, adrenergic nerve fibers that secrete dopamine⁽¹⁵⁾. Myometrium does not have specific receptors for this catecholamine, but dopamine is able to interact with other uterine structures: nervous endings, endometrium, respectively, in pregnancy, decidua or placenta.

Parasympathetic or cholinergic innervation

Parasympathetic postganglionic fibers, which have their origin in the inferior hypogastric ganglion, are

distributed almost exclusively in the cervix. Cholinergic endings possess vesicles that contain acetylcholine, stored together with ATP, proteoglycans and other proteins. Acetylcholine stimulates specific membrane receptors (muscarinic receptors, M₁₋₅ and nicotinic receptors, NN,M), on uterine myocytes existing only two muscarinic receptor subtypes: M₂ and M₃^(13,16).

In vitro, acetylcholine administration induces an increase in frequency and intensity of myometrial contractile waves, without a significant change in tone (phasic type effect).

Ocytotic action of acetylcholine is mainly due to M₃ receptor stimulation, located on the myometrial smooth muscle cells membrane (table 1).

Although M₃ receptors are present on the membrane of all myometrial cells, cholinergic endings are distributed only to the cervical area and isthmus and only in small numbers in the rest of the uterus. So, the parasympathetic stimulation causes cervical fibers contraction, less isthmus area muscle contraction (isthmus corresponds to the low segment, in late gestation), with little, or no effect on the uterine body. The contraction of the circular muscle bundles of the cervix, during pregnancy, has a content effect, preventing the

premature rupture of membranes and, hence, the early expulsion of the fetus.

Neuronal autonomic co-transmission

It is known that in the final button vesicles, belonging to both adrenergic and cholinergic endings, alongside with classical mediators: noradrenaline, and acetylcholine, respectively it is a whole range of other substances able to modulate smooth muscle cell activity. They realize the so-called phenomenon of "co-transmission", which is more frequent and more intense on parasympathetic fibers.

Moreover, it was found that the postganglionic neurons, both sympathetic and parasympathetic, if they are in culture, in the absence of physiological nerve stimulation (which normally is done by acetylcholine), released mainly, sometimes exclusively, other mediators⁽¹⁷⁾.

Another feature is that, frequently, there are involved neurotransmitters with opposite effects, contractile and relaxing.

Sympathetic co-transmission

Noradrenaline is released from the sympathetic neurons, through exocytosis, together with ATP, cromogranin, dopamine β -hydroxylase and other compounds (Hoffman and Lefkowitz, 2001).

ATP has, itself, uterine contractil effect (table 1).

Adrenergic vesicles contain also, different substances with:

- ocytotic effect^(18,19,20,21): tahikinins (SP), the most important and NKA, NPY and galanin;
- tocolytic effect: CGRP, ANP,⁽²²⁾ and NO⁽¹⁹⁾.

Also can be released somatostatin⁽¹⁸⁾, but its role on uterine modulation is uncertain.

Moreover, there are adrenergic endings that generate co-transmission noradrenaline/acetylcholine⁽²³⁾.

Parasympathetic co-transmission

Among the parasympathetic endings, acetylcholine is removed from the vesicles, together with ATP, proteoglycans and other compounds^(17,18,19,24), with:

- ocytotic effect: ATP, NPY or
- tocolytic effect: CGRP, VIP and NO (table 1).

Parasympathetic endings can also contain endogenous opioids (endorphins and enkephalins), for which the myometrium has specific receptors, but their role in shaping the uterine contraction, if any, is very low. These substances, however, decrease the release of neurotransmitters from local nerve endings and also can interact with specific receptors, located on the membrane of connective tissue cells, endometrium, placenta etc.

Non-adrenergic/non-cholinergic autonomic innervation

There are nerve endings, belonging to the autonomic nervous system, which release neither noradrenaline nor acetylcholine. These are the so-called nerves:

- peptidergic, which secrete exclusively one or more peptides: SP, cholecystokinin, VIP, galanin, bombesin, CGRP^(18,19,25) or
- purinergic, having as sole mediator ATP⁽²⁰⁾.

There are also, axonal endings that secrete dynorphins or enkefalins⁽¹⁹⁾ (generally, in combination with other peptides or ATP) or NO (also, alone or with other mediators)^(18,19).

Most non-adrenergic/non-cholinergic nerves are present in the digestive tract, but exist, also, in genitourinary tract.

An important feature is that the non-adrenergic/non-cholinergic fibers act as sensitive and effector fibers in the same time. Therefore, the stimulation of their endings cause the reflex release of the compounds contained in the same endings or other endings, belonging to the same axons⁽²⁶⁾. ■


References

1. Collins J.J., Wilson K. and Papka R.E., Secretoneurin-immunoreactive nerves in the female rat reproductive system. *Soc Neurosci*, 1998; 24:1618.
2. Berkeley K.J., Hubsher C.H. and Wall P.D., Neuronal responses to stimulation of the cervix, uterus, colon and skin in the rat spinal cord. *J Neurophysiol*, 1993; 69: 545-56.
3. Hotta H., Uchida S., Shimura M. et al., Uterine contractility and blood flow are reflexively regulated by cutaneous afferent stimulation in anaesthetized rats. *J Auton Nerv Syst*, 1999; 75(1): 23-31.
4. Cunnigam F.G., MacDonalds P.C., Gant N.F. et al., Parturition. In: Williams Obstetrics, 2001; 11: 2512-91.
5. Guyton A.C. and Hall J.E., Contraction and Excitation of Smooth Muscle. In: *Textbook of Medical Physiology*. 2001, W.B.Saunders comp; 8: 90-1.
6. Richeria A., Viettro L., Chavey-Genaroa R., Burnstock G. et al., Effects of infantile/prepurtal chronic estrogen treatment andndf chemical sympathetomy with guanethidine on developing cholinergic nerves of the rat uterus. *J Histochem Cytochem*, 2002; 50: 839-50.
7. Quinn M.J. and Kirk N., Differences in uterine innervation at hysterectomy. *Am J Obstet Gynecol*, 2002; 187(6): 1515-9.
8. Mhaouty-Kodja S., Bouet-Alard R., Limon-Boulez I. et al., Molecular diversity of adenylyl cyclases in human and rat myometrium. *JBC*, 1997; 272(49): 31100-6.
9. Hoffman B.B., Lefkowitz R.J. and Taylor P., Neurotransmission: The Autonomic and Somatic Motor Nervous Systems. In: *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 2001; 6: 135-6.
10. Cohen-Tannoudji J., Vivat V., Heilman J. et al., Regulation by progesterone of high-affinity state of myometrial β -adrenergic receptor and of adenylyl cyclase activity in the pregnant rat. *J Mol Endocrinol*, 1991; 6: 137-45.
11. Dahle L.O., Andersson R.G., Berg G. et al., Alpha-adrenergic receptors in human myometrium: changes during pregnancy. *Gynecol Obstet Invest*, 1993; 36(2): 75-80.
12. Kitazawa T., Maezono Y. and Taneike T., The mechanism of alpha(2)-adrenoceptor agonist-induced contraction in the longitudinal muscle of porcine uterus. *Eur J Pharmacol*, 2000; 390(1-2): 185-95.
13. Hoffman B.B. and Lefkowitz R.J., Catecholamines, Sympathomimetic Drugs and Adrenergic Receptor Antagonists. In: *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 2001; 10: 199-248.
14. Denedy M.C., Houlihan D.D., McMillan H. et al., Beta2- and beta3-adrenoceptor agonists: human myometrial selectivity and effects on umbilical artery tone. *Am J Obstet Gynecol*, 2002; 187(3): 641-7.
15. Kim M.O., Kim J.H., Choi W.S. et al., Colocalization of dopamine D1 and D2 receptor mRNAs in rat placenta. *Mol Cell*, 1997; 7(6): 710-4.
16. Abdalla F.M., Abreu L.C. and Porto C.S., Effect of estrogen on intracellular signaling pathways linked to activation of M(2)- and M(3)-muscarinic acetylcholine receptors in the rat myometrium. *Mol Cell Endocrinol*, 2000; 25(160): 17-24.
17. Lindh B. and Hokfelt T., Structural and functional aspects of acetylcholine peptide coexistence in the autonomic nervous system. *Prog Brain Res*, 1990; 84: 175-91.
18. Czaja K., Wasowicz K., Podlasz P. et al., Distribution and immunohistochemical characterisation of paracervical neurons innervating the oviduct in the pig. *Folia Morphol*, 2001; 60(3): 205-11.
19. Elfvin L.G., Holmberg K., Emson P. et al., Nitric oxide synthase, choline acetyltransferase, catecholamine enzymes and neuropeptides and their colocaliation in the anterior pelvic ganglion, the inferior mesenteric ganglion and the hypogastric nerve of male guinea pig. *J Chem Neuroanat*, 1997; 14(1): 33-49.
20. Lindh B., Hokfelt T., Elfvin L.G. et al., Topography of NPY, somatostatin and VIP-immunoreactive, neuronal subpopulations in the guinea pig celiac-superior mesenteric ganglion and their projections to the pilorus. *J Neurosci*, 1986; 6: 2371-83.
21. Patak E.N., Ziccone S., Storx M.E. et al., Activation of neurokinin NK(2) receptors by tachykinin peptides causes contraction of uterus in pregnant

- women near term. Mol Hum Reprod, 2000; 6(6): 549-54.
22. Mione M.C., Ralevic V. and Burnstock G., Peptides and vasomotor mechanisms. Pharmacol Ther, 1990; 46: 429-68.
 23. Miguel A.M., Holmberg K., Xu Z.Q. et al., Localization of choline acetyltransferase in rat peripheral sympathetic neurons and its coexistence with nitric oxide synthase and neuropeptides. Proc Natl Acad Sci, 1995; 92: 11819-23.
 24. Andersen R.L., Gibbins I.L. and Morris J.L., Five inhibitory transmitters coexist in pelvic autonomic vasodilator neurons. Neuroreport, 1997; 8(14): 3023-8.
 25. Papka R.E. and Trauring H.H., Galanin-immunoreactive nerves in the female rat paracervical ganglion and uterine cervix; distribution and reaction to capsaicin. Cell Tissue Res, 1989; 257(1): 41-51.
 26. Katzung B.G. Introduction to Autonomic Pharmacology. In: Basic & Clinical Pharmacology, 2001; 6: 75-91.
 27. ZhuGe R., Li S., Chen T.H. et al., Alpha2-adrenergic receptor-mediated Ca^{2+} influx and release in porcine myometrial cells. Biol Reprod, 1997; 56(5): 1343-50.
 28. Adolffson P.I., Dahle P.O., Berg G. et al., Characterization of alpha2-adrenoceptor subtypes in pregnant human myometrium. Gynecol Obstet Invest, 1998; 45(3): 145-50.
 29. Naghashpour M. and Dahl G., Sensitivity of myometrium to CGRP varies during mouse estrous cycle and in response to progesterone. Am J Physiol Cell Physiol, 2000; 278: C561-C569.
 30. Niiro N., Nishimura J., Hirano K. et al., Mechanisms of galanin-induced contraction in the rat myometrium. Br J Pharmacol, 1998; 124: 1623-32.
 31. Reid I.A., Vasoactive Peptides. In: Katzung's Basic & Clinical Pharmacology, 2001; 17: 303-5.
 32. Aitken H., Poyser N.L. and Hollingsworth M., The effect of P2y receptor agonist and adenosine on prostaglandin production by the guinea-pig uterus. Br J Pharmacol, 2001; 132(3): 709-21.
 33. Kuriyama H., Kitamura K., Itoch T. et al., Physiological Features of Visceral Smooth Muscle Cells, With Special Reference to Receptors and Ion Channels. Physiol Rev, 1998; 78: 811-920.
 34. Fredholm B.B., Abbraccio M.P., Burnstock G. et al., Nomenclature and classification of purinoreceptors. Pharmacol Rev, 1994, 46: 143-156.
 35. Cintado C.G., Pinto F.M., Devillier P. et al., Increase in neurokinin B expression and in tachykinin NK3 receptor-mediated response and exproression in the rat uterus with age. Biol Reprod, 2001; 299(3): 934-8.
 36. Lowenstein C.J., Dinerman J.L. and Snyder S.H., Nitric oxide: a physiological messenger. Annu Intern Med, 1994; 120: 227-37.
 37. Barnes P.J., Baraniuk J.N. and Belvisi M.G., Neuropeptides in the respiratory tract. Am Rev Respir Dis, 1991; 144: 1187-98.
 38. Gorodeski G.I., Expression, regulation and function of P2x4 purinergic receptors in human cervical epithelial cells. Am J Physiol Cell Physiol, 2002; 282(1): C84-C93.
 39. Nakashima M. and Vanhoutte P.M., Isoproterenol causes hyperpolarization through opening of ATP-sensitive potassium channels in vascular smooth muscle of the canine saphenous vein. J Pharmacol Exp Ther, 1995; 272: 379-84.
 40. Amiot F., Leiber D., Marc S. et al., GRP-prefering bombesin receptors increase generation of inositol phosphates and tension in rat myometry. Am J Physiol, 1993; 265: C1579-87.
 41. Tanaka C. and Nishizuka Y., The protein kinase C family for neuronal signaling. Annu Rev Neurosci, 1994; 17: 551-67.
 42. Dong Y.L., Vegiraju S., Gangula P.R. et al., Expression and regulation of Calcitonin Gene-Related Peptide receptor in rat placentas. Biol Reprod, 2002; 67: 1321-6.
 43. Modzelewska B., Sipowicz M.A., Saavedra J.E. et al., Involvement of K⁺ATP channels in nitric oxide-induced inhibition of spontaneous contractile activity of the nonpregnant human myometrium. Biochem Biophys Res Commun, 1998; 253: 653-7.
 44. Niki I., Kelly R.P., Ashcroft S.J.H. et al., ATP-sensitive K-channels in HIT T15 b-cells studied by patch-clamp methods, 86Rb efflux and glibenclamide binding. Pflügers Arch, 1989; 415: 47-55.
 45. Adelwoehrer N.E. and Mahner W., Hexoprenaline activates potassium channels of human myometrial myocytes. Arch Gynecol Obstet, 1993; 254(4): 179-84.
 46. Bonev A.D., Robertson B.E. and Nelson M.T., Inward rectify K⁺ current from rat coronary artery smooth muscle cells. Biophys J, 1994; 66: A237.
 47. Bajo A.M., Juarranz M.G., Valenzuela P. et al., Expression of vasoactive intestinal peptide (VIP) receptors in human uterus. Peptides, 2000; 21(9): 1383-8.
 48. Potvin W. and Varma D.R., Down-regulation of myometrial atrial natriuretic factor receptors by progesterone and pregnancy and up-regulation by oestrogen in rats. J Endocrinol, 1991; 131(2): 259-66.
 49. Yuen P.S.T. and Garbers D.L., Guanine cyclase-linked receptors. Annu Rev Neurosci, 1992; 15: 193-225.
 50. Dos Reis A.M., Dam T.V., Mukaddam-Daher S. et al., Characterization of natriuretic peptide receptors in the rat uterus. Endocrinol, 1995; 136(10): 4247-53.
 51. Bradley K.K., Buxton I.L.O., Barber J.E. et al., Nitric oxide relaxes human myometrium by a cGMP-independent mechanism. Am J Physiol Cell Physiol, 1998; 275: C1668-C1673.
 52. Nikitenko L.L., Brown N.S., Smith D.M. et al., Differential and cell-specific expression of calcitonin receptor-like receptor and receptor activity modifying proteins in the human uterus. Mol Hum Reprod, 2001; 7(7): 655-64.
 53. Whitley J.C., Giraud A.S. and Shulkes A., Expression of gastrin-releasing peptide (GRP) and GRP receptors in the pregnant human uterus at term. J Clin Endocrinol metab, 1996; 81(11): 3944-50.

Homeopatia anti-stres

Îngrijiți-vă simțarea psihică folosind medicamente anti-stres care nu înduc dependență și nici efecte secundare asupra vigilenței. Homeopatia ajută organismul să înfrunte mai bine pe termen scurt situațiile stresante. Tratatamentul homeopatic poate fi urmat și ca tratament de fond, contribuind la restabilirea echilibrului nervos, la controlul judicios al reacțiilor cauzate de stres și la o mai bună focalizare mentală.



✓ Fără somnolență diurnă

✓ Fără dependență

✓ Fără interacțiuni cu alte medicamente sau cu alcoolul

✓ Se administrează tuturor categoriilor de vârstă, femeilor însărcinate și persoanelor aflate în tratament polimedicamentos

Regăsește-ți calmul cu



2 comprimate de 3 ori pe zi

Acest medicament este produs în conformitate cu normele medicale. Este recomandat să se consulte un medic specialist sau să se consulte un medic de familie. Dacă apar reacții adverse neplăcute, sărbătorile și medicul dumneavoastră vor fi informați.

Viza ANMDM 127 din 07.04.2011

LABORATOARE
BOIRON
www.boiron.com